A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine

Vaccine

Volumn 31, Issue 20, 2013, Pages 2471-2476

  Cheng, Aristine ^a,b   Fung, Chang Phone ^c   Liu, Chia Chyi ^d   Lin, Yi Tsung ^c   Tsai, Hsih Yeh ^a,b   Chang, Shan Chwen ^b   Chou, Ai Hsiang ^d   Chang, Jui Yuan ^d   Jiang, Ren Huei ^d   Hsieh, Yi Chin ^d   Su, Ih Jen ^d   Chong, Pele Choi Sing ^d   Hsieh, Szu Min ^b  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Enterovirus 71; Phase I; Vaccine

Indexed keywords

ENTEROVIRUS 71 VACCINE; IMMUNOGLOBULIN G; INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG SAFETY; ENTEROVIRUS 71; FATIGUE; FEMALE; FLATULENCE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA; INJECTION SITE PAIN; MALE; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NORMAL HUMAN; NOSE OBSTRUCTION; OROPHARYNX PAIN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEROCONVERSION; SIDE EFFECT; VIRUS NEUTRALIZATION; XEROSTOMIA;

ADJUVANTS, IMMUNOLOGIC; ADULT; ALUM COMPOUNDS; ANIMALS; ANTIBODY FORMATION; CERCOPITHECUS AETHIOPS; ENTEROVIRUS; ENTEROVIRUS INFECTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; VACCINATION; VACCINES, INACTIVATED; VERO CELLS; VIRAL VACCINES; YOUNG ADULT;

EID: 84877072126     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.03.015     Document Type: Article

References (25)

1. Oberste M.S., Maher K., Kilpatrick D.R., Pallansch M.A. Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification. J Virol 1999, 73(March (3)):1941-1948.
2. Melnick J.L., Schmidt N.J., Mirkovic R.R., Chumakov M.P., Lavrova I.K., Voroshilova M.K. Identification of Bulgarian strain 258 of enterovirus 71. Intervirology 1980, 12(6):297-302.
3. Hagiwara A., Tagaya I., Yoneyama T. Epidemic of hand, foot and mouth disease associated with enterovirus 71 infection. Intervirology 1978, 9(1):60-63.
4. Kennett M.L., Birch C.J., Lewis F.A., Yung A.P., Locarnini S.A., Gust I.D. Enterovirus type 71 infection in Melbourne. Bull World Health Organ 1974, 51(6):609-615.
5. Shimizu H., Utama A., Yoshii K., Yoshida H., Yoneyama T., Sinniah M., et al. Enterovirus 71 from fatal and nonfatal cases of hand, foot and mouth disease epidemics in Malaysia, Japan and Taiwan in 1997-1998. Jpn J Infect Dis 1999, 52(February (1)):12-15.
6. Wang C.Y., Li Lu F., Wu M.H., Lee C.Y., Huang L.M. Fatal coxsackievirus A16 infection. Pediatr Infect Dis J 2004, 23(March (3)):275-276.
7. Shindarov L.M., Chumakov M.P., Voroshilova M.K., Bojinov S., Vasilenko S.M., Iordanov I., et al. Epidemiological, clinical, and pathomorphological characteristics of epidemic poliomyelitis-like disease caused by enterovirus 71. J Hyg Epidemiol Microbiol Immunol 1979, 23(3):284-295.
8. Huang C.C., Liu C.C., Chang Y.C., Chen C.Y., Wang S.T., Yeh T.F. Neurologic complications in children with enterovirus 71 infection. N Engl J Med 1999, 341(September (13)):936-942.
9. Ho M., Chen E.R., Hsu K.H., Twu S.J., Chen K.T., Tsai S.F., et al. An epidemic of enterovirus 71 infection in Taiwan. N Engl J Med 1999, 341(September (13)):929-935.
10. Lin TY, Hsia SH, Huang YC, Wu CT, Chang LY. Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2003 February;36(3):269-74.
11. Lin T.Y., Twu S.J., Ho M.S., Chang L.Y., Lee C.Y. Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg Infect Dis 2003, 9(March (3)):291-293.
12. Cardosa M.J., Perera D., Brown B.A., Cheon D., Chan H.M., Chan K.P., et al. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerg Infect Dis 2003, 9(April (4)):461-468.
13. Chou A.H., Liu C.C., Chang C.P., Guo M.S., Hsieh S.Y., Yang W.H., et al. Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PloS ONE 2012, 7(4):e34834.
14. Chang J.Y., Chang C.P., Tsai H.H., Lee C.D., Lian W.C., Ih Jen S., et al. Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. Vaccine 2012, 30(January (4)):703-711.
15. Liu C.C., Guo M.S., Lin F.H., Hsiao K.N., Chang K.H., Chou A.H., et al. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PloS ONE 2011, 6(5):e20005.
16. Liu C.C., Chou A.H., Lien S.P., Lin H.Y., Liu S.J., Chang J.Y., et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 2011, 29(June (26)):4362-4372.
17. Chang H.W., Liu C.C., Lin M.H., Ho H.M., Yang Y.T., Chow Y.H., et al. Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genogroup B isolates. J Virol Methods 2011, 173(May (2)):189-195.
18. Chou AH, Liu CC, Chang JY, Jiang R, Hsieh YC, Tsao A, et al. Formalin-inactivated EV71 vaccine candidate induced strong cross-neutralizing antibody responses in young adults. PLoS neglected tropical diseases 2013;Revision.
19. Kuo HSea Communicable Diseases of Interest to the Public: Enterovirus. Center for Disease Control, Taiwan. 2005 Annual Report 2005:53-5.
20. Luo S.T., Chiang P.S., Chao A.S., Liou G.Y., Lin R., Lin T.Y., et al. Enterovirus 71 maternal antibodies in infants, Taiwan. Emerg Infect Dis 2009, 15(April (4)):581-584.
21. Li Y.P., Liang Z.L., Gao Q., Huang L.R., Mao Q.Y., Wen S.Q., et al. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 2012, 30(May (22)):3295-3303.
22. Meng F.Y., Li J.X., Li X.L., Chu K., Zhang Y.T., Ji H., et al. Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: an open label, phase 1 clinical trial. Hum Vaccines Immunother 2012, 8(May (5)):668-674.
23. Zhu F.C., Wang J.Z., Li X.L., Liang Z.L., Ge H.M., Meng F.Y., et al. Reactogenicity and immunogenicity of an enterovirus 71 vaccine in chinese healthy children and infants. Pediat Infect Dis J 2012, 31(November (11)):1158-1165.
24. Eickhoff T.C., Myers M. Workshop summary. Aluminum in vaccines. Vaccine 2002, 20(May (Suppl. 3)):S1-S4.
25. Jefferson T., Rudin M., Di Pietrantonj C. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. Lancet Infect Dis 2004, 4(February (2)):84-90.